Penumbra surpasses Q1 sales estimates with revenue increasing 16.3%, leading to stock soaring

From Stock Story Media: 2025-04-23 17:32:00

Penumbra (NYSE:PEN) reported Q1 CY2025 results beating revenue expectations, with sales up 16.3% year on year to $324.1 million. Non-GAAP profit of $0.83 per share was 24.4% above estimates. Full year revenue expected to be around $1.35 billion. Market capitalization currently at $10.72 billion. Constant currency revenue rose 16.9% year on year. Penumbra develops innovative medical devices for vascular diseases and healthcare rehabilitation solutions. Sales grew at 17.4% CAGR over the last five years. Analysts project 12.6% revenue growth over the next 12 months. Operating margin at 12.4%. EPS grew at 34.5% CAGR over the last five years, reaching $0.83 in Q1.

The medical devices and supplies industry, including cardiology, neurology, and vascular care, benefits from balanced innovation and predictable revenue streams. Penumbra’s revenue growth, operating margin, and EPS show strong performance. Analysts expect continued revenue growth. The industry faces challenges like regulatory approval and pricing pressures. Penumbra’s sales growth and profitability demonstrate quality and demand for its products. The company’s operating margin and EPS growth indicate improved efficiency and profitability. Overall, Penumbra’s Q1 results exceeded expectations, showing positive performance and potential for future growth.



Read more at Stock Story Media: Penumbra’s (NYSE:PEN) Q1 Sales Beat Estimates, Stock Soars